Treating the Endothelium to Restore Insulin Sensitivity
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00402194
Recruitment Status :
First Posted : November 22, 2006
Results First Posted : September 24, 2013
Last Update Posted : September 24, 2013
Indiana University School of Medicine
Information provided by (Responsible Party):
Indiana University ( Indiana University School of Medicine )
Recent studies suggesting an effect of cardiovascular therapies to prevent diabetes remain unexplained. We hypothesize that these therapies improve vascular endothelial function allowing improved actions of insulin in the vasculature, which comprise a significant portion of insulin's metabolic action. We therefore propose to measure insulin-mediated glucose disposal and insulin-mediated vasodilation before and after 12 weeks' therapy with Losartan (an angiotensin receptor blocker) or placebo, in a randomized design. Subjects will include 28 subjects with impaired glucose tolerance, which is generally accompanied by both insulin resistance and impaired vascular function. With this number of participants we have a 90% chance of showing a statistically significant and clinically meaningful effect of insulin on leg vascular resistance, and an even higher chance of showing a difference in insulin's metabolic effects. Exclusion criteria will include frank hypertension, diabetes, or hypercholesterolemia, and biochemical or other contraindications to losartan therapy. The primary endpoint for statistical analysis will be the invasive measure of insulin-stimulated endothelial function. We anticipate an improvement in both vascular and metabolic measures of insulin action following Losartan therapy but no change from untreated baseline following placebo.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Male and female
Obese, defined as Males: BMI >28 or > 30% fat by DEXA scan or Bod Pod; Females: BMI >30 or > 33% fat by DEXA scan or Bod Pod
Weight stable over at least 4 months
Diabetes mellitus (ADA criteria)
Age <20 or > 55 yrs
Blood pressure >160/90 or < 90/65 mmHg
Total cholesterol >240 or LDL cholesterol >160 mg/dL
Baseline elevations in AST or ALT > 3X ULN
Baseline elevation in creatinine >1.6 ng/mL
Unexplained baseline elevation in creatine kinase > 3X ULN
Concurrent significant chronic medical illness including, but not limited to, human immunodeficiency virus infection, Syphilis, hepatitis B infection, or hepatitis C infection
Known hypersensitivity or intolerance to the study agents